Recommended diagnostic criteria for paraneoplastic neurological syndromes
- PMID: 15258215
- PMCID: PMC1739186
- DOI: 10.1136/jnnp.2003.034447
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Abstract
Background: Paraneoplastic neurological syndromes (PNS) are defined by the presence of cancer and exclusion of other known causes of the neurological symptoms, but this criterion does not separate "true" PNS from neurological syndromes that are coincidental with a cancer.
Objective: To provide more rigorous diagnostic criteria for PNS.
Methods: An international panel of neurologists interested in PNS identified those defined as "classical" in previous studies. The panel reviewed the existing diagnostic criteria and recommended new criteria for those in whom no clinical consensus was reached in the past. The panel reviewed all reported onconeural antibodies and established the conditions to identify those that would be labelled as "well characterised". The antibody information was obtained from published work and from unpublished data from the different laboratories involved in the study.
Results: The panel suggest two levels of evidence to define a neurological syndrome as paraneoplastic: "definite" and "possible". Each level can be reached combining a set of criteria based on the presence or absence of cancer and the definitions of "classical" syndrome and "well characterised" onconeural antibody.
Conclusions: The proposed criteria should help clinicians in the classification of their patients and the prospective and retrospective analysis of PNS cases.
Comment in
-
Recommended diagnostic criteria for paraneoplastic neurological syndromes.J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1090. doi: 10.1136/jnnp.2004.038489. J Neurol Neurosurg Psychiatry. 2004. PMID: 15258205 Free PMC article. No abstract available.
Similar articles
-
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. doi: 10.1212/NXI.0000000000001014. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34006622 Free PMC article.
-
"Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.J Neurol Sci. 2015 May 15;352(1-2):58-61. doi: 10.1016/j.jns.2015.03.027. Epub 2015 Mar 23. J Neurol Sci. 2015. PMID: 25824848
-
Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.Acta Neurol Scand Suppl. 2011;(191):83-8. doi: 10.1111/j.1600-0404.2011.01549.x. Acta Neurol Scand Suppl. 2011. PMID: 21711262 Review.
-
Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.J Neurol Sci. 2015 Jan 15;348(1-2):41-5. doi: 10.1016/j.jns.2014.10.040. Epub 2014 Nov 5. J Neurol Sci. 2015. PMID: 25467140
-
[Paraneoplastic neurological syndrome and autoantibodies].Brain Nerve. 2013 Apr;65(4):385-93. Brain Nerve. 2013. PMID: 23568986 Review. Japanese.
Cited by
-
Paraneoplastic Cerebellar Degeneration Associated with Breast Cancer: A Case Report and a Narrative Review.Brain Sci. 2024 Feb 14;14(2):176. doi: 10.3390/brainsci14020176. Brain Sci. 2024. PMID: 38391750 Free PMC article. Review.
-
Paraneoplastic Neurological Syndromes as Initial Presentation of Tumors: An Eight-Year Single-Center Experience.J Clin Med. 2024 Jan 31;13(3):824. doi: 10.3390/jcm13030824. J Clin Med. 2024. PMID: 38337520 Free PMC article.
-
PNMA2 forms immunogenic non-enveloped virus-like capsids associated with paraneoplastic neurological syndrome.Cell. 2024 Feb 15;187(4):831-845.e19. doi: 10.1016/j.cell.2024.01.009. Epub 2024 Jan 31. Cell. 2024. PMID: 38301645
-
Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.Curr Treat Options Oncol. 2024 Jan;25(1):42-65. doi: 10.1007/s11864-023-01157-1. Epub 2024 Jan 10. Curr Treat Options Oncol. 2024. PMID: 38198120 Review.
-
Case Report: Anti-mGluR5 antibody-negative Ophelia syndrome with failed lymph node biopsy due to steroid therapy.Front Immunol. 2023 Dec 8;14:1188154. doi: 10.3389/fimmu.2023.1188154. eCollection 2023. Front Immunol. 2023. PMID: 38162652 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous